Kraig Biocraft Laboratories, Inc. (KBLB) Form 424B3 — May 22, 2026

Kraig Biocraft Laboratories filed a prospectus supplement updating its registration statement with its Q1 2026 financial results, which reveal a net loss of $942,720 and zero revenue. The company reported a cash position of $2.89 million against total liabilities of $10.78 million, resulting in a working capital deficit of $7.67 million. The filing includes a critical going-concern warning, stating that substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and capital deficiency. Management acknowledged that current cash resources are insufficient to meet planned business objectives without additional financing.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.